WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together with its Drug Product Packaging Center (DPPC), have received GMP certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The certification positions WuXi Biologics to provide end‑to‑end commercial manufacturing services — covering both drug substance and drug product — for an anti-PD-L1 monoclonal antibody used in cancer immunotherapy.
Based on the five-day inspection, MFG2, DP1 and DPPC successfully passed ANVISA's assessment with zero findings. The inspection results demonstrate WuXi Biologics' robust quality management system, mature GMP execution, and efficient cross-functional collaboration, while verifying the company's comprehensive capabilities to support client needs for global commercial manufacturing and supply.
Within WuXi Biologics' global GMP manufacturing network, MFG2, DP1 and DPPC collectively provide integrated, end-to-end capabilities spanning large-scale biologics drug substance manufacturing, clinical and commercial drug product fill-finish, and customized packaging, meeting regulatory requirements across major markets worldwide. Together, these capabilities enable seamless manufacturing and reliable commercial supply for innovative biologic therapies.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "Receiving ANVISA GMP certification reflects WuXi Biologics' continued commitment to global quality and compliance standards, and further validates our international standards across facilities, quality systems, and GMP execution. Looking ahead, we will continue to leverage our world-class quality system and end-to-end manufacturing capabilities to enable clients' global commercialization strategies, including entry into Latin America. By accelerating the delivery of high-quality, affordable biologics, we are helping to broaden access to innovative biologics for patients around the world."
WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's rigorous quality standards. As of the end of 2025, it has successfully passed 46 regulatory inspections, including 22 conducted by the FDA and EMA, and secured 136 facility license approvals. The company also holds an industry-leading record, achieving a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics has passed more than 1,800 GMP quality audits by global clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network. Its world-class quality and compliance capabilities underpin long-standing trust from clients worldwide.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)
*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-receives-brazil-anvisa-gmp-certification-to-enable-global-commercial-manufacturing-of-innovative-cancer-immunotherapy-302814124.html
SOURCE WuXi Biologics
